Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

| --- | --- | --- | --- | |--------------|--------------------|--------------------|--------------------| | PK Parameter | GMR (%) | 90% CI LB | 90% CI UB | | | Test vs. Reference | Test vs. Reference | Test vs. Reference | | Cmax | 105 | 92 | 120 | | AUC0-∞ | 97 | 88 | 107 | | AUC0-t | 88 | 80 | 99 | LPCN 1154 treatment was well tolerated with no sedation nor somnolence events observed. All events were mild to moderate, and no severe or serious adverse events occurred. Reported study related events were ve ...